It’s hard to imagine why someone would pretend to have a terminal illness, but it happens more often than you’d think. From ...
For instance, we will offer free exchanges for expired medications and 24x7 pharmacist support, which will help build customer trust. We will also accelerate the rollout of online medical ...
RAHWAY, N.J., March 6, 2025 /PRNewswire/ -- A sinus infection, known as sinusitis, is one of the most common medical conditions. But in some cases, it can come with dangerous complications. There ...
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...
Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.
Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results